Correction: Cook et al. An Optimized Bioassay for Screening Combined Anticoronaviral Compounds for Efficacy against Feline Infectious Peritonitis Virus with Pharmacokinetic Analyses of GS-441524, Remdesivir, and Molnupiravir in Cats. Viruses 2022, 14, 2429

Error in Table

In the original publication [1], incorrect numerical data were entered into the last three numbers in the AUC column of Table 5 and this mistake was not recognized by our review team. This error was identified by Sally Coggins who brought it to our attention. Corrected Table 5 appears below.

Table 5. Pharmacokinetic parameters for GS-441524 after a single IV dose of RDV (7 mg/kg) in 3 cats.

Cat ID	Cmax (ng/mL; μM)	Tmax (h)	T1/2 (h)	AUC (h*ng/mL)
20-045	1730 (5.94)	0.5	5.3	14,271
21-001	1960 (6.73)	1	5.7	15,291
21-004	2320 (7.97)	1	4.5	9924
Mean	2003 (6.88)	0.83	5.2	13,162
SD	297 (1.0)	0.29	0.6	2850

Table 5. Pharmacokinetic parameters for GS-441524 after a single IV dose of RDV (7 mg/kg) in 3 cats.

Cat ID	Cmax (ng/mL; μM)	Tmax (h)	T1/2 (h)	AUC (h*ng/mL)
20-045	1730 (5.94)	0.5	5.3	14,271
21-001	1960 (6.73)	1	5.7	15,291
21-004	2320 (7.97)	1	4.5	9924
Mean	2003 (6.88)	0.83	5.2	13,162
SD	297 (1.0)	0.29	0.6	2850

Text Correction

With regard to the correction of Table 5, a correction has been made to Section 3.4, Paragraph 3.

“Finally, in the IV RDV cohort, GS-441524 exhibited an average plasma Cmax of 2003 ng/mL (6.9 μM) at a corresponding Tmax of 0.83 h and an average AUC_0-24 value of 13,162 h*ng/mL (45 μM*h; average C24 = 64 ± 32 ng/mL, 0.22 ± 0.11 μM) (Table 5).”

The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.